Neffy: A latest needle-free epinephrine

Anaphylaxis is a rapid-onset, potentially fatal allergic reaction requiring prompt administration of epinephrine. Until recently, epinephrine autoinjectors have dominated emergency treatment, but challenges, such as needle phobia, improper use, and poor carriage rates, reduce their real-world efficacy. Neffy (ARS-1; epinephrine nasal spray) introduces a needle-free, intranasal route for epinephrine delivery. This review examines the clinical evidence, pharmacological profile, indications, and safety data for Neffy and discusses implications for clinical practice.